Clinical studies have shown that topiramate, a sulphamate-substituted fructopyranose derivative, might be an efficacious treatment for alcohol dependence, smoking cessation within an alcohol-dependent population, and cocaine dependence. Mechanistically, topiramate's therapeutic effects have been hypothesized to be due to inhibition of cortico-mesolimbic dopamine function, the primary substrate that governs the acquisition, maintenance, and reinstatement of goal-directed behaviour towards seeking abused drugs. Predicated on this hypothesis, we tested in 10 methamphetamine-dependent individuals (three females) whether low-or high-dose (15 or 30 mg i.v.) methamphetamine-induced positive subjective effects and reinforcement can be antagonized by low-or high-dose (100 or 200 mg orally) topiramate using a placebo-controlled, cross-over, factorial design. Methamphetamine administration was associated with orderly, prototypical, and significant increases on measures of stimulation, euphoria, craving, and reinforcement ; however, some dysphoric symptoms also emerged. Topiramate alone showed a nonsignificant trend towards mild reductions in positive mood and reinforcement ; yet topiramate appeared to accentuate the appreciation of methamphetamine-induced stimulation and euphoria significantly, but not craving or reinforcement. The experimental combination of topiramate and methamphetamine appeared to be safe and well tolerated, with few adverse events. Acute dosing with up to 200 mg topiramate appears to enhance, rather than attenuate, the positive subjective effects of methamphetamine. Perhaps this indicates a partial inhibition of methamphetamine's reinforcing effects. Thus, testing chronically administered or higher doses, or both, of topiramate would be necessary to determine conclusively whether or not it can attenuate the positive subjective and reinforcing effects of methamphetamine.
Introduction
Methamphetamine abuse remains an important and growing health problem in the USA, particularly on the Pacific Coast (U.S. Department of Health and Human Services, 1997 ; Rawson et al., 2002) , as well as in Asia (Chung et al., 2004 ; Kulsudjarit, 2004) . Given the high association between methamphetamine use and mental illness, violence, and HIV infection (Halkitis et al., 2001 ; Cho and Melega, 2002) , there has been renewed effort to develop an effective pharmacotherapeutic agent. Nevertheless, few clinical studies have been conducted due to the paucity of promising candidate medications (Johnson et al., 1999) .
d-Methamphetamine exerts its behavioural effects by increasing cortical and midbrain levels of dopamine (DA), serotonin, and, to a smaller extent, norepinephrine through the added effect of pre-synaptic inhibition of uptake and enhanced release (McKenna et al., 1991 ; Weihmuller et al., 1991) . Despite these effects at various aminergic neurotransmitters, methamphetamine's reinforcing behavioural effects principally associated with its abuse liability, like those of other drugs of abuse, are presumed to be those associated with the facilitation of corticomesolimbic DA neurotransmission (Hemby et al., 1997) . Therefore, a promising candidate medication for treating methamphetamine dependence would be expected to reduce cortico-mesolimbic DA neurotransmission.
Previously, we showed that topiramate, a sulphamate-substituted fructopyranose derivative, is efficacious at improving the drinking outcomes of alcohol-dependent individuals (Johnson et al., 2003a) . Furthermore, in a secondary analysis of the cohort of nicotine-and alcohol-dependent individuals, topiramate also facilitated smoking cessation (Johnson et al., 2005) . Other investigators have shown that topiramate might also be efficacious at reducing cocaine intake in treatment-seeking, cocaine-dependent individuals (Kampman et al., 2004) . These therapeutic effects of topiramate have been hypothesized to be due to a reduction in cortico-mesolimbic DA levels (Johnson, 2004 ; Johnson et al., 2003a Johnson et al., , 2005 . While topiramate's potential anti-dopaminergic effect had only been investigated directly in a single study, the results showed that it attenuated nicotine-induced mesolimbic DA release (Schiffer et al., 2001) . It is, therefore, reasonable to predict that topiramate would attenuate the behavioural effects of methamphetamine associated with its abuse liability, presumably by antagonizing cortico-mesolimbic DA function.
Using a human laboratory paradigm as a bridge between preclinical and clinical studies, we tested, in a double-blind experiment, the hypothesis that topiramate (100 or 200 mg orally), compared with placebo, would reduce methamphetamine (15 or 30 mg i.v.)-induced measures of positive subjective effect and reinforcement in 10 non-treatment-seeking, methamphetamine-dependent individuals.
Materials and methods

Subjects
We studied 10 DSM-IV-diagnosed (APA, 1994) methamphetamine-dependent individuals (seven males) between the ages of 31 and 44 yr (mean 37 yr) who were recruited by local newspaper, radio, and television advertisements. These subjects did not meet diagnostic criteria for any other Axis I psychiatric disorder except nicotine dependence. See Table 1 for additional demographic data. All subjects gave informed consent before being included in the study.
Experimental design
This study was approved by the Institutional Review Board at The University of Texas Health Science Center at San Antonio (UTHSCSA) and, therefore, was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. We conducted a double-blind, placebo-controlled, cross-over design, administering oral doses of topiramate (0, 100, and 200 mg) as a pretreatment before intravenous doses of methamphetamine (0, 15, and 30 mg). The 3r3 factorial combination of topiramate and methamphetamine resulted in a sequence of the nine treatments administered to each subject in an order determined by a 9r9 latin square design. The designated topiramate dose (100 or 200 mg) was administered in two divided doses. The first dose (50 or 100 mg respectively) was given at 20:00 hours the evening before the session, and the second dose was given at 08:30 hours the morning of the session. Treatment sessions were conducted on a MondayWednesday-Friday schedule so that there was a 2-to 3-d interval between sessions. All subjects were hospitalized for the entire study (27 d) in the University Clinical Psychopharmacology Laboratory (UCPL), a residential research unit at the University Hospital, the main teaching hospital of UTHSCSA.
Choice of medication dose and its preparation
The high topiramate dose was chosen to correspond with the apparent minimal effective daily dose observed in the clinical trial for alcohol dependence (Johnson et al., 2003a) . Notably, however, this was an estimate because in that study, the topiramate dose was confounded by the effect of time, as a paradigm of escalating dose over an 8-wk period was employed. The lower topiramate dose was half of that effective dose. For methamphetamine, the high dose (30 mg) was approximately that which would have been achieved by a 70-kg individual, using data from a previous study in which robust subjective effects were observed (Johnson et al., 1999) . The low methamphetamine dose was half of the maximum dose. Topiramate tablets (25 g) were obtained from Ortho-McNeil Pharmaceutical Inc. (Raritan, NJ, USA) and were over-encapsulated in royal blue size 0 capsules (Shionogi Qualicaps Inc., Whitsett, NC, USA) and filled with cornstarch. Placebo topiramate capsules were identical in both colour and size and contained only cornstarch. The intravenous methamphetamine doses chosen were in accordance with National Institute on Drug Abuse (NIDA) guidelines for methamphetamine administration. Methamphetamine-HCl as 20-mg/ml ampoules suitable for human intravenous administration was obtained from NIDA. For injection, methamphetamine solution was mixed with sterile 0.9 % w/v normal saline to produce 0-, 15-, and 30-mg/3-ml injection volumes. Placebo methamphetamine was 3 ml of 0.9 % w/v saline without methamphetamine.
Laboratory conditions
The study took place at the UCPL. Infusion procedures were performed in a testing room of approximately 18r11 ft. After insertion of a venous catheter with a three-way stopcock adapter into a nondominant arm or hand vein, subjects were seated in a comfortable chair and instructed not to rise or talk during the experiment. Methamphetamine or placebo was infused through polyethylene tubing with an automated syringe pump. Cardiovascular function was continuously monitored under close medical supervision. Euphoria and drug reinforcement were measured with subjective assessments of mood, drug preference and liking, and general well-being, along with a choice procedure (see below).
Experimental measures
Self-report measures of drug liking and drug-induced euphoria have become hallmarks of abuse liability assessment Jasinski et al., 1984 ; Roache and Griffiths, 1989) . Abuse liability studies typically add other measures of general mood state and specific expected target symptoms to establish an overall profile of drug effects . Measures used in the present study are standard for human abuse liability assessment. Based on these methods, we utilized the following rating scales.
Multiple-Choice Questionnaire (MCQ)
The MCQ is a measure of preference for drug over monetary reward. The MCQ we used was a modification of the paper-and-pencil task originally developed by Griffiths et al. (1993) . At 30 min (MCQ1) and again at 2 h (MCQ2) after the methamphetamine infusion, subjects were asked to indicate their preference between that day's methamphetamine effects and a designated amount of money. Over a series of 72 questions, the amount of the monetary alternative was sequentially increased from $0.25 to $25 to determine the point at which the methamphetamine injection was no longer preferred over money. This is called the 'cross-over value', an amount of money slightly in excess of the monetary value of the drug (i.e. the drug is preferred at lesser amounts but money is preferred at this and greater amounts). The cross-over value derived from this questionnaire (MCQ-price) was used as one of the primary measures of the abuse potential of any particular drug combination. As reported by Griffiths et al. (1993 Griffiths et al. ( , 1996 , the validity of this measure as a true reflection of drug preference is enhanced by actually providing subjects with the commodity (i.e. drug or money) they preferred as one of their randomly selected choices. Thus, during a training and familiarization session, subjects were instructed that at the end of the study, all the choices they reported on the MCQ would be entered into a ' lottery ' and one of these choices would be randomly selected, at which time they would receive the consequence of their choice. On the last day of the experiment (day 11), subjects received as a consequence either the money or a methamphetamine injection they chose on one of the ' lottery ' choices, drawn at random from the MCQ responses of the previous nine sessions.
End-of-Day Questionnaire (EDQ)
At 16:30 hours (6 h post-methamphetamine dose), subjects were asked to express their feelings about the effects of the methamphetamine they received earlier in the day (Roache and Meisch, 1995 ; Roache et al., 1995a) . In response to the statement 'I would use this methamphetamine dose again ', they were asked to use a pencil to place a perpendicular mark on a 100-mm line labelled (left to right) 'not at all ' to 'extremely '. Comments also were elicited on what they liked and disliked about the effect of the earlier dose of methamphetamine.
Visual Analogue Scale of Methamphetamine Effects (VAS-M)
For the VAS-M, subjects are asked to use a pencil to place a perpendicular mark on a 100-mm line labelled (left to right) 'not at all' to 'extremely '. We evaluated methamphetamine effects by implementing adjectival scales that have been used previously in human abuse liability assessments of cocaine Higgins et al., 1990) , d-amphetamine (Johnson et al., 1996 ; Silverstone et al., 1992) , methamphetamine (Johnson et al., 1999) , and benzodiazepines (Johnson et al., 1996 ; Roache et al., 1995b) . They were : (1) measures of euphoria ('high ', ' like ', 'rush or thrill ', 'feel good or elated ') ; (2) general measures of stimulant effect/side-effect (' aroused or stimulated ', 'mind-racing ', 'slow or lethargic ', 'nervous ', ' shaky or jittery ', 'nauseous '), and (3) measures of craving ('crave ', 'desire ', 'want methamphetamine ', 'could refuse methamphetamine '). The VAS-M was completed 15 min before the methamphetamine/placebo infusion and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180, 240 , and 300 min after the infusion.
Global Rating of Stimulation (GRS)
The GRS assesses the effects of stimulants on overall mood state (Johnson et al., 1996 ; Silverstone et al., 1992 ) with a five-point scale (0, normal ; 1, slightly light-headed, restless, or speeded-up ; 2, moderately light-headed, restless, or speeded-up ; 3, very much light-headed, restless, or speeded-up, and 4, extremely light-headed, restless, or speeded-up). Subjects are asked to circle one answer. The GRS was completed at the same time points as the VAS-M.
Addiction Research Center Inventory (ARCI)
The ARCI is a 49-item true/false questionnaire empirically reduced to a five-factor subscale based on responses to drugs from different pharmacological classes (Haertzen et al., 1963) . The morphine/Benzedrine (MBG), Benzedrine (BG), and amphetamine (A) factor scales assess stimulant effects, the MBG scale being the measure of drug-induced euphoria . The lysergic acid diethylamide (LSD) scale assesses effects often considered to be dysphoric. Finally, the pentobarbital, chlorpromazine, and alcohol (PCAG) scale is a measure of sedation. The ARCI was completed 30 min before the morning dose of topiramate/placebo and again 30 min before the methamphetamine/placebo infusion. To assess methamphetamine effects, it was repeated again at 45, 90, and 180 min following the intravenous infusion.
Profile of Mood States (POMS)
The POMS is a standardized five-point interval rating scale composed of adjectives describing different moods or feeling states (McNair et al., 1971) . The 65-item version scores seven factors : tension-anxiety, depression-dejection, fatigue, confusion-bewilderment, anger-hostility, friendliness, and vigour. An eighth factor, elation, is scored with an additional four-point rating POMS-elation (POMS-E) scale, a 12-item questionnaire with five adjectives from the POMS plus seven more adjectives. The POMS and POMS-E were completed at the same times as the ARCI.
General procedures
All subjects were caffeine abstinent while residing on the research unit, and cigarette smokers were limited to smoke breaks several times throughout the day but never within 1 h of the methamphetamine infusion. Generally, the limited smoke breaks resulted in the smoking of only 5-10 cigarettes/d. On a separate experimental day before double-blind testing, all subjects were trained on the proper use of the rating scales. Also, during that session, a single-blind dose of methamphetamine (15 mg i.v.) was administered to ensure that the subject had clinical tolerance to the methamphetamine infusion procedures. This initial injection also familiarized subjects with the test room and conditions before the double-blind part of the experiment began.
All females were stabilized on the oral contraceptive pill before testing to control for menstrual cycle effects (Di Paolo, 1994 ; King et al., 1986) and to prevent pregnancy.
Test day procedures
In the evening before the session day, we administered the first dose of topiramate or matching placebo at 20:00 hours and subjects were instructed to retire to bed at 23:00 hours. On the morning of the test session, each subject provided a urine sample at 07:00 hours before receiving a standard hospital breakfast. Using an OnTrak TesTcup 1 (Varian Inc., Palo Alto, CA, USA), we tested each subject's urine for the presence of opiates, amphetamines, cocaine, benzodiazepines, or barbiturates and took a breath alcohol concentration. The urine drug screen and breath alcohol concentration had to be negative and zero, respectively, for further testing to proceed. At 08:00 hours, subjects scored their impressions at baseline on the ARCI, POMS, and POMS-E ; then, we placed a venous catheter in each subject's nondominant arm or hand. At 08:30 hours, subjects took the second half of their topiramate dose. At 09:45 hours, we attached electrodes (including chest leads) to each subject to perform a 12-lead electrocardiogram and to monitor the electrocardiogram and heart rate continuously. Additionally, we attached a blood pressure cuff to the subject to permit frequent (every 2 min) automated blood pressure measurements. All these cardiovascular parameters were collected electronically through a Spacelabs Ultraview 1 1050, Module 90496 cardiac monitor (Spacelabs Medical Inc., Issaquah, WA, USA). Also, we used a 2.2-ml length of polyethylene tubing to attach the venous catheter to an automated infusion pump (Baxter International Inc., Deerfield, IL, USA). At 10:00 hours, each subject completed the ARCI, POMS, and POMS-E and a baseline recording on the VAS-M. Then, at 10:30 hours, the attending physician commenced the intravenous infusion of 3 ml methamphetamine or matching placebo for 60 s by activating the syringe pump. Thereafter, each subject completed the MCQ and subjective self-report questionnaires according to the schedule detailed previously. Lunch was provided at 13:00 hours. At 15:00 hours, the attending physician performed a second 12-lead electrocardiogram and a final assessment of subject health, and the electrodes were disconnected. We performed regular safety checks of each subject's health status throughout the test day until the time for the subject to retire to bed at 23:00 hours.
Statistical analysis
Two MCQ-price/dose values (ranging between $0 and $25) were each analysed by a repeated-measures mixed model (McCulloch and Searle, 2001) . The model specification was designed to test for methamphetamine and topiramate main effects as well as their interaction, adjusting for time (in day) effect. A similar analysis was carried out for 'use again ', which measures the predisposition to use the methamphetamine dose in the EDQ. Multiple observations were made at different time-points in the day for each combination of methamphetamine and topiramate for measures including VAS-M, GRS, ARCI, POMS, and POMS-E. To reduce the dimensionality, we used the area under the curve (AUC) and peak value in each day to summarize the observations. The AUC for each subscale from 0 to 5 h was determined by the trapezoidal rule. The peak value was taken to be the maximum value during that day. The mixed model was used to compare the AUCs and peak values between different combinations of methamphetamine and topiramate while adjusting for the day effect.
A factor analysis was used to summarize the VAS-M data . We classified the 14 VAS-M subscales into three component scales : 'euphoria ' (sum of ' high', 'like ', 'rush ', and 'elated '), 'stimulate ' (sum of 'stimulated ', ' racing ', 'lethargic ', 'nervous ', 'shaky ', and ' nauseous'), and 'crave ' (sum of 'craving ', 'desire ', 'want ', and 100 minus 'refuse ').
Data for the VAS-M, GRS, ARCI, POMS, and POMS-E in Tables 2 and 3 are presented as their means and confidence intervals, thus obviating individual cell contrasts, which would inflate the error rate due to multiple statistical testing.
The type I error rate was specified at a significance level of 0.05, and all tests were two-sided. All data were analysed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA). S-PLUS 1 2002 (Insightful Corp., Seattle, WA, USA) was used to generate some of the plots.
Results Tables 2 and 3 
MCQ and EDQ
There was a significant methamphetamine dosedependent increase in the value of the drug over money on both the MCQ1 and MCQ2 (p<0.0001) ; the higher compared with the lower methamphetamine dose had the greater monetary value. Notably, topiramate on its own had a non-significant effect to decrease both MCQ1 and MCQ2 values. While topiramate appeared to accentuate the effect of methamphetamine to increase the value of the drug over money, this effect was non-significant. There was no significant interaction effect between methamphetamine and topiramate on MCQ dollar values. For ' use again' in the EDQ, both methamphetamine and topiramate had significant main effects plus the interaction effect. Participants with the higher methamphetamine and topiramate doses had the greatest propensity to want to 'use again', and the interaction term indicated that topiramate enhanced the methamphetamine effect significantly.
VAS-M
On the AUC measure, methamphetamine had a significant effect on the ' euphoria ' and 'stimulate ' component scales. The higher dose of methamphetamine tended to elevate the levels of 'euphoria ' and 'stimulate ' (p<0.001). Topiramate appeared to increase both ' euphoria ' and 'stimulate ' levels in participants receiving either the 15-or 30-mg dose of methamphetamine ; however, there was only a significant effect for 'stimulate ' (p=0.02). None of the interactions were significant. Neither methamphetamine nor topiramate had a significant main or interaction effect on the 'crave ' component scale.
On the peak measure, methamphetamine had a significant positive main effect on all three component scales (p<0.0001), whereas topiramate had significant effects on only 'euphoria ' and ' stimulate ' (p<0.01). The higher dose of topiramate increased the levels for both. The interaction between methamphetamine and topiramate was significant for the 'euphoria ' (p<0.01) and ' stimulate ' components (p=0.02).
GRS
On both the AUC and peak measures, methamphetamine had a significant effect to increase the GRS (p<0.0001). Topiramate on its own had a trend towards decreasing GRS scores ; in contrast, topiramate accentuated significantly the positive effect of methamphetamine on the peak GRS (p=0.007).
The interaction between methamphetamine and topiramate was not significant for either the AUC or peak GRS measure.
ARCI
On both the AUC and peak measures, methamphetamine had a significant positive effect on the MBG (p=0.03), BG (pf0.05), and A (p<0.01) subscales ; however, topiramate alone had a statistically insignificant tendency to reduce these effects. Topiramate did not significantly accentuate the effects of methamphetamine on the MBG, BG, and A subscales. Topiramate alone had no effect on the LSD subscale, but in combination with methamphetamine it appeared to increase the AUC and peak measures of the LSD subscale. None of the interactions were significant.
POMS and POMS-E
On the AUC measure, methamphetamine increased significantly only the tension-anxiety subscale (p=0.03). On the peak measure, methamphetamine increased the tension-anxiety and vigour measures significantly. On the POMS-E scale, the effects of methamphetamine or topiramate, either alone or in combination, did not differ significantly from placebo. Topiramate had no significant effect on any of the POMS or POMS-E factors, and there was no interaction between methamphetamine and topiramate on any of the AUC or peak measures.
Adverse events
There were no serious or significant adverse events in any subject throughout treatment. Three subjects reported having adverse events. The first subject experienced three adverse event episodes : at the 30-mg dose of methamphetamine with the 100-mg daily dose of topiramate, there were slight S-T changes, elevated blood pressure (to 164/109 mmHg), one isolated atrial premature contraction, and a description of palpitations ; at 30 mg methamphetamine and 200 mg topiramate, there was a slight change in P waves and an associated change in the R-R interval, and at 15 mg methamphetamine and 0 mg topiramate, there was an isolated premature atrial contraction. The second subject had an episode of mild sinus arrhythmia (at 118 beats/min). The third subject reported skin discomfort with the precordial leads. The recorded arrhythmias all followed methamphetamine infusion. No arrhythmia required specialized intervention or medication. All resolved spontaneously. None of these adverse events were considered to be of significant clinical importance.
Discussion
Generally, methamphetamine produced significant, orderly, and prototypical increases on 'stimulate ', 'euphoria ', and 'crave '. Methamphetamine was reinforcing, and preference for its administration was demonstrated as an increase in MCQ cross-over value as well as increased reports of wanting to ' use again' ; however, methamphetamine was not associated with an increase on the elation factor of the POMS-E. Further, methamphetamine administration was associated with a significant increase in tension-anxiety on the POMS and enhancement on the LSD (i.e. dysphoria) scale of ARCI. Hence, while the predominant effect of experimentally administered methamphetamine is increased positive mood, it is noteworthy that this is accompanied by some dysphoric symptoms. We have described previously the possibility that experimentally administered methamphetamine can produce a mixed mood state ; however, subjects for that study were healthy human volunteers, not addicts (Johnson et al., 1999) . At that time, we postulated that this phenomenon was probably due to 'over-stimulation ' in naive subjects and would not be seen in addicts. Now that it appears that the phenomenon is seen in both addicts and healthy human volunteers, we are forced to consider other possibilities. Obviously, it could be that higher doses of experimentally administered methamphetamine might be needed to produce robust and uniform feelings of euphoria and stimulation in the human laboratory. While higher methamphetamine doses might mimic street drug use more closely, safety and ethical concerns would prohibit such an experimental paradigm. Of course, we considered the possibility that this mixed mood state might simply be due to the novelty of the experimental paradigm compared with drug taking in more naturalistic settings ; however, we thought that this was unlikely to be the primary or only reason, given the extensive familiarization period before formal testing. Also, it is quite plausible that even among addicted individuals, the context in which drug taking occurs might cause cognitive reinterpretation of the experience and the appreciation of relative euphoria or dysphoria. Further, there could be a subset of addicted individuals who experience dysphoria for methamphetamine taking but who might continue to use it for other desirable but nonmood-related reasons, such as the need to enhance performance and cognition or lose weight. Notably, the trend was for topiramate alone to reduce positive subjective mood and to be antireinforcing ; however, these observations did not achieve statistical significance. Indeed, the striking effect we observed was that topiramate accentuated markedly the positive subjective effects of methamphetamine. Although this might suggest an additive or synergistic effect of topiramate on methamphetamine-induced positive subjective mood, that was, of course, unlikely because topiramate on its own did not enhance mood. We propose that the more likely explanation is that because topiramate as opposed to placebo administration was associated with a mild negative mood, when methamphetamine was given later, the appreciation of its positive subjective effects and self-reported propensity to 'use again ' were greater. This hypothesis is supported by an additional finding. That is, topiramate did not enhance significantly the methamphetamineinduced increases in reinforcement (i.e. on the MCQ) or the 'crave ' component of the VAS-M. While it could be argued that this might be because of the small subject numbers, the degree of overlap in the confidence intervals would indicate that such a phenomenon would not be possible to demonstrate, even if the direction of the effect were sustained, in a cohort many times the size of that in the present experiment. Indeed, the direction of the effect for the high topiramate dose was to reduce the craving produced by low-dose methamphetamine on the VAS-M.
Of course, we considered the possibility of kinetic interaction between topiramate and methamphetamine, with the plasma level of methamphetamine being higher in the presence of topiramate than in its absence. Although we did not perform a full kinetic examination, our preliminary data from sequentially timed blood draws (not shown) did indicate a slight trend for topiramate to increase methamphetamine plasma levels, but this did not achieve statistical significance. Topiramate tends to alkalinize the urine, an effect that has been associated with increased propensity for nephrolithiasis (Kuo et al., 2002 ; Lamb et al., 2004) . Since the urinary excretion of amphetamines is enhanced by acidification, topiramate might have impeded the renal elimination of methamphetamine, which led to slightly higher plasma levels (Davis et al., 1971; Poklis et al., 1998) . While the magnitude of this increase in methamphetamine plasma level by topiramate would be unlikely to explain the apparent enhancement of methamphetamine's subjective and behavioural effects by topiramate, it could become a more important consideration in studies where topiramate is administered chronically. It is tempting to speculate, although we have no direct evidence for this, that such an effect in a clinical study might lead to lower methamphetamine consumption as less would be needed to obtain a similar level of positive subjective or behavioural effect.
There are at least four important limitations to this experiment that should place the importance of our study results in context.
First, the strength of acute pharmacological drug interaction studies, which comprise the majority of medication development experiments, is that they enable determination of tolerance, dosing paradigms, and exploration of important drug interactions that can affect the adverse events profile (Johnson et al., 2003b) or therapeutic efficacy (Johnson and Cowen, 1993) . Importantly, however, acute dose drug interaction studies are limited and may offer an incomplete or misleading picture as to the potential for clinical efficacy. This is because clinical trials involve chronicnot acute -medication administration, and issues of long-term rather than short-term tolerance become important (Johnson et al., 1999) . Further, the highly controlled experimental environment is artificial, and methamphetamine dosing is limited for safety reasons. Additionally, many medications require repeated or chronic administration to manifest their predominant pharmacological effect and clinical efficacy, and this might not be captured with an acute dosing paradigm. For example, the use of selective serotonin reuptake inhibitors to treat anxiety is a good example of a class of drugs that, acutely, can increase anxiety but, chronically, can reduce anxiety (Burghardt et al., 2004) . Interestingly, the clinical studies conducted with topiramate in addictive disorders all point to a slow onset of effect starting after several weeks of its repeated administration ; this could be why a prominent effect to antagonize methamphetamine-induced reinforcement was not demonstrated with this acute dosing paradigm. We, therefore, propose that the next step would be to test the effects of repeated dosing with topiramate on the positive subjective and reinforcing effects of methamphetamine.
Second, methamphetamine has non-dopaminergic (e.g. serotonergic) pharmacological effects contributing to its positive subjective and reinforcing effects that might not be neuronal targets for the effects of topiramate. Certainly, methamphetamine's serotonin and noradrenergic transmission-enhancing effects are greater than those of any of the other drugs (i.e. alcohol, nicotine, and cocaine) against which topiramate has been demonstrated to show clinical efficacy. It is, therefore, possible that any reductive effects of topiramate exerted on methamphetamine-induced positive subjective effect and reinforcement would always be partial.
Third, our experimental paradigm assumed that one of the two chosen doses of topiramate would be sufficient to antagonize pharmacologically the positive subjective and reinforcing effects of either of the two doses of methamphetamine. Since there are no prior human laboratory studies testing this particular medication-drug interaction, it is plausible that different and perhaps higher doses of topiramate might have been more likely to produce the predicted response. Indeed, it is tempting to speculate that the topiramate doses we have used might have been partially anti-reinforcing, thereby producing a somewhat paradoxical response to enhance acutely the subjective appreciation for methamphetamine. This phenomenon has been well demonstrated in animal studies, where partial inhibition of the reinforcing effects of a drug simply made the animal work harder to obtain the drug in the short term (Adinoff, 2004 ; Dackis and Gold, 1985) . In humans, this might, arguably, be exhibited as an enhancement of positive subjective mood or propensity to use the drug. Extinguishing this ' rebound ' effect could be achieved by using a higher pharmacological dose of the medication if the dose-response curve were linear, or by using a lengthier period of dosing. Therefore, an extension to our previous proposal would be to test the effects of higher and multiple doses of repeatedly or chronically administered topiramate on the positive subjective and reinforcing properties of methamphetamine.
Fourth, a different methodological approach might be needed to test more clearly the potential antireinforcing effects of topiramate. Given that there was a non-significant although fairly consistent trend for topiramate to appear to be anti-reinforcing when administered alone, the use of bipolar scales might have made this effect more evident.
We can, however, draw from this experiment three important conclusions that have implications for clinical studies. First, there appears to be no important adverse interaction between topiramate and methamphetamine that would preclude further study in either a human laboratory or clinical setting. Second, if indeed topiramate does have an effect to reduce methamphetamine reinforcement that becomes manifest with chronic dosing, it would be important to select motivated individuals for testing in clinical trials -i.e. those who are less likely to ' sample ' methamphetamine until topiramate's full pharmacological effects have been established. Finally, it would be prudent to test multiple and certainly higher doses than 200 mg topiramate to increase the likelihood of finding an efficacious dose for treating methamphetamine dependence.
